Litcius/Paper detail

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Yared Hailemichael, Daniel H. Johnson, Noha Abdel‐Wahab, Wai Chin Foo, Salah-Eddine Bentebibel, May Daher, Cara Haymaker, Khalida Wani, Chantal Saberian, Dai Ogata, Sang T. Kim, Roza Nurieva, Alexander J. Lazar, Hamzah Abu‐Sbeih, Faisal Fa’ak, Antony Mathew, Yinghong Wang, Adewunmi Falohun, Van Trinh, Chrystia M. Zobniw, Christine Spillson, Jared K. Burks, Muhammad O. Awiwi, Khaled M. Elsayes, Luisa M. Solis Soto, Brenda Melendez, Michael A. Davies, Jennifer A. Wargo, Jonathan L. Curry, Cassian Yee, Gregory Lizée, Shalini Singh, Padmanee Sharma, James P. Allison, Patrick Hwu, Sühendan Ekmekçioglu, Adi Diab

2022Cancer Cell344 citationsDOIOpen Access PDF

Topics & Concepts

BlockadeImmunologyImmune systemImmunotherapyColitisImmune checkpointMedicineAutoimmunityCytotoxic T cellCD8Cancer researchBiologyInternal medicineReceptorBiochemistryIn vitroCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionCancer, Stress, Anesthesia, and Immune Response
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity | Litcius